HPV Year 1 BC:

Adverse events following immunization in passive surveillance

Monika Naus, MD, FRCPC
Director, Immunization Programs
BC Centre for Disease Control
June 12, 2009
Syncope After Vaccination --- United States, January 2005--July 2007

Anaphylaxis following quadrivalent human papillomavirus vaccination

Julia M.L. Brotherton MD MPH, Mike S. Gold MD, Andrew S. Kemp MD PhD, Peter B. McIntyre MD PhD, Margaret A. Burgess MD, Sue Campbell-Lloyd RN, on behalf of the New South Wales Health HPV Adverse Events Panel

Published at www.cmaj.ca on Sept. 1, 2008.

European Medicines Agency
Press office

London, 19 February 2009
Doc. Ref. EMEA/CHMP/103339/2009

PRESS RELEASE
European Medicines Agency recommends continued vaccination with Gardasil

The European Medicines Agency (EMEA) has reviewed the available information on the two cases of status epilepticus with myoclonus (repeated and prolonged seizures and loss of consciousness) reported in two girls vaccinated with the cervical cancer vaccine Gardasil in Spain.
HPV vaccine: reported events from first season of grade 6 and 9 immunizations in BC

- Cohort: ~23,000 girls in each of grades 6 and 9, receipt of ~90,000 doses between September 1/08 and June 30/09
- AEFI: 114 events reported from 91 recipients (appointment dates from September 2008 to April 2009 inclusive)
  - 16 “serious” events among 15 individuals reported (selected if reported as: anaphylaxis, convulsion/seizure, encephalopathy, meningitis and/or encephalitis, anaesthesia/paresthesia, paralysis, Guillain-Barré syndrome, other severe or unusual events)
  - 3 hospitalized (2 syncope with tonic/clonic episode, 1 ‘other severe/ unusual’ without details)

Source: iPHIS data, Epidemiology services, BC Centre for Disease Control
Adverse events following HPV immunization reported through passive system, BC

Symptom reporting rate for HPV immunization, Sept 2008 to April 2009  N=91

- Fever
- Redness/swelling/pain
- Allergic reaction - wheezing
- Allergic reaction - localized puffiness/edema
- Rash or hives
- Anaphylaxis
- Other severe or unusual

Rate per 100,000

HPV alone
HPV + concurrent vaccine(s)
HPV vaccine: 16 reported “serious” events to April 09: grade 6 and 9 immunizations in BC

<table>
<thead>
<tr>
<th>Reaction type</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>3</td>
</tr>
<tr>
<td>Anaesth/ Paresth 24 hr+</td>
<td>3</td>
</tr>
<tr>
<td>Syncope with tonic/ clonic activity</td>
<td>6</td>
</tr>
<tr>
<td>Other severe or unusual event</td>
<td>4</td>
</tr>
</tbody>
</table>

4 “other severe or unusual”:
- 2 with no comments
- 1 blurred vision
- 1 autoimmune hemolytic anemia

Recoded from “other severe or unusual”:
- 6 fever+
- 1 urinary incontinence

Source: iPHIS data, Epidemiology services, BC Centre for Disease Control
Canadian Adverse Events Following Immunization Surveillance System – to December 2008

- 310 reports to date since onset of marketing
  - 32 per 100,000 (cf. USA ~50)
  - 2 per 100,000 for serious (N=19)
    - 7 Paresthesias
    - 2 Appendicitis
    - 1 each of:
      - Anaphylaxis
      - Breast abscess
      - New onset DM
      - Febrile illness with persistent microhematuria
      - Conversion psychosis
      - ADEM presentation in 2006, now MS
  - 11 hospitalizations but only 1 definitely related (syncopal fall with head injury)
  - 1 GBS with 20 week interval post immunization

Source: Dr. Barbara Law, Chief, Vaccine Safety, PHAC